Key result
Low-dose atrial natriuretic peptide significantly reduced the incidence of acute kidney injury within 48 hours after aortic arch surgery compared with placebo (30% vs 73%, P=0.014).
Why the study?
Does low-dose intravenous atrial natriuretic peptide reduce the incidence of acute kidney injury in patients undergoing elective repair of an aortic arch aneurysm?
RCT (n=42)
randomly assigned
No
Does low-dose intravenous atrial natriuretic peptide reduce the incidence of acute kidney injury in patients undergoing elective repair of an aortic arch aneurysm?
Absolute Event Rate: 30% vs 73%
p-value: p=0.014
Low-dose intravenous atrial natriuretic peptide significantly reduces the incidence of acute kidney injury within 48 hours after elective aortic arch surgery.
Supports low-dose atrial natriuretic peptide for AKI prevention after aortic arch surgery; extends renoprotective evidence to this high-risk RCT population.
BACKGROUND: Acute kidney injury (AKI) after surgery is associated with an increased risk of adverse events and death. Atrial natriuretic peptide (ANP) dilates the preglomerular renal arteries and inhibits the renin-angiotensin axis. A low-dose ANP infusion increases glomerular filtration rate after cardiovascular surgery, but it is not known whether it reduces the incidence of AKI or the mortality rate. OBJECTIVE: To evaluate whether an intravenous ANP infusion prevents AKI in patients undergoing aortic arch surgery requiring hypothermic circulatory arrest. DESIGN: A randomised controlled study. SETTING: Operating room and intensive care unit at Kawasaki Saiwai Hospital, Kanagawa, Japan. PATIENTS: Forty-two patients with normal preoperative renal function undergoing elective repair of an aortic arch aneurysm. INTERVENTION: Patients were assigned randomly to receive a fixed dose of ANP (0.0125 μg (-1) kg(-1) min) or placebo. The infusion was started after induction of anaesthesia and continued for 24 h postoperatively. MAIN OUTCOME MEASURES: The primary end-point was the incidence of AKI within 48 h after surgery. RESULTS: AKI developed in 30% of patients who received ANP compared with 73% of patients who received placebo (P = 0.014). Intraoperative urine output was almost 1 l greater in patients who received ANP (1865 ± 1299 versus 991 ± 480 ml in the control group, P = 0.005). However, there were no differences in mean arterial pressure or number of episodes of hypotension between the groups. Length of hospital and intensive care stays were not significantly different, nor was there a difference in 30-day mortality. No patients required haemodialysis or continuous renal replacement therapy. CONCLUSION: We found that an intravenous infusion of ANP at 0.0125 μg kg(-1) min(-1) is an effective intervention for reducing the incidence of postoperative AKI, and appears to afford a degree of renal protection during and after cardiovascular surgery. TRIAL REGISTRATION: Kawasaki ANP trial, UMIN Clinical Trials Registry ID: UMIN000011650.
No takes yet. Share an insight, caveat, or question.
Mori et al. (2014) conducted an RCT in aortic arch aneurysm requiring surgery (n=42). Atrial natriuretic peptide (ANP) vs. placebo was evaluated on incidence of AKI within 48 h after surgery (p=0.014). Low-dose atrial natriuretic peptide significantly reduced the incidence of acute kidney injury within 48 hours after aortic arch surgery compared with placebo (30% vs 73%, P=0.014).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: